Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonging Adjuvant Tamoxifen in Breast Cancer
NCT00003016Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Oct 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tamoxifen in breast cancer (2 arms), sponsored by University of Oxford. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003016.